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malignancy induced thyroid dysfunction is uncommon but
receiving increased attention. Progressive destruction of
the thyroid gland caused by metastatic malignancy can
contribute to hypothyroidism and potentially eventual
myxedema coma.2 Here, we report a patient with
impending myxedema coma diagnosed as lung cancer with
thyroid-gland metastasis in conclusion.
A 72-year-old man presented to our Emergency Depart-
ment with altered consciousness, progressive dyspnea, and
general edema over 2 weeks. Chest radiograph revealed
bilateral pleural effusion and pericardial effusion, which
were lymphocyte-predominant exudate. Laboratory in-
vestigations showed that sodium levels had dropped to
110 mmol/L (normal range: w135e147 mmol/L). Serum
free-T4 levels were also below the detectable level
(<0.4 ng/dL) and thyroid-stimulating hormone levels had
increased to 71.0 uIU/mL (normal range:
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thyroid sonography, 3.6- and 3.5-cm diameter heteroge-
neous hypoechoic masses with diffuse microcalcification
were observed in the right and left lobes of the thyroid
gland, respectively. Fine-needle aspiration revealed ma-
lignant cells. Following thyroxine and glucocorticoid
replacement, the patient underwent total thyroidectomy.
Pathology demonstrated that the normal thyroid gland had
been almost completely replaced by metastatic carcinoma
cells that were positive for TTF-1, CK7, and napsin A, but
negative for thyroglobulin and PAX-8 (Figure 1). A meta-
static tumor of pulmonary origin was favored. Chest
computed tomography confirmed a 5.5-cm diameter mass
in the right middle lobe of the lung, with multiple enlarged
mediastinal lymph nodes. The final diagnosis was stage IV
lung adenocarcinoma with thyroid-gland metastasis,
causing secondary hypothyroidism and impending
myxedema coma. Erlotinib was prescribed due to the
presence of the EGFR L858R mutation in the biopsied tumor
cells. The patient responded well, and the level of con-
sciousness returned to normal status within 2 months.
However, the disease progressed with pleural seeding,
pericardial effusion, and massive pleural effusion after 10
months of treatment.
Myxedema coma constitutes an emergency situation,
with high mortality rates ranging from w25% to 60%.1 Mostma coma as the initial presentation of lung cancer, Journal of the
a.2016.09.009
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).
Figure 1 Normal thyroid gland architecture was destroyed and largely replaced by cancer cells [A, 40; B, 200 (hematoxylin
and eosin stain)]. Both thyroid follicular cells (arrow) and cancer cells (arrow head) were positive for TTF-1 (C, 200), but only
thyroid follicular cells were positive for thyroglobulin (D, 200).
2 C.-I. Shen et al.
+ MODELcases are related to thyroidectomy or with a previous his-
tory of radioiodine therapy.1 There are increasing case re-
ports of hypothyroidism caused by treatment with a
tyrosine kinase inhibitor, most notably sunitinib.3 The
clinical presentation is systemic failure, including respira-
tory failure and altered mental status. The treatment
consists of supportive care and emergent thyroid-hormone
replacement.1
Tumor metastasis as the cause of hypothyroidism is rare,
with autopsy studies reporting the incidence of thyroid
metastasis in patients with known malignancy ranging from
1.9% to 24%.4 The most common origins are kidney, breast,
gastrointestinal tract, and lung.4 Pathology with an ancil-
lary panel of immune-histochemical staining is needed to
make a final diagnosis.4 In our case, the presence of a
classical EGFR mutation supported the diagnosis. Surgical
resection provides evidence for both diagnosis and treat-
ment; however, the benefits and disadvantages remain
controversial.5
There is increased awareness of thyroid dysfunction
caused by metastatic cancer-cell infiltration. In most cases,
thyroid function remains normal; however, both thyrotoxi-
cosis and hypothyroidism have been reported.2 To clinicalPlease cite this article in press as: Shen C-I, et al., Impending myxede
Formosan Medical Association (2016), http://dx.doi.org/10.1016/j.jfmphysicians, it is important to note that thyroid metastasis is
among the differential diagnoses of hypothyroidism, espe-
cially in patients with thyroid nodules.
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